Evidence map›Paper›PMID 31565079›Full record

ArticleAnalytical methods : advancing methods and applications2019

Ultrasensitive Multi-Species Detection of CRISPR-Cas9 by a Portable Centrifugal Microfluidic Platform.

Christopher R Phaneuf, Kyle J Seamon, Tyler P Eckles, Anchal Sinha, Joseph S Schoeniger, Brooke Harmon, Robert J Meagher, Vinay Abhyankar, Chung-Yan Koh

Abstract read
In one paragraph

Article in Analytical methods : advancing methods and applications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Mechanisms regulating the CRISPR-Cas systems.Frontiers in microbiology · 2023
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Engineering fiber anisotropy within natural collagen hydrogels.American journal of physiology. Cell physiology · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Anti-CRISPRs: The natural inhibitors for CRISPR-Cas systems.Animal models and experimental medicine · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christopher R Phaneuf *Biotechnology and Bioengineering, Sandia National Laboratories, Livermore, CA 94550, USA.
Kyle J Seamon *Systems Biology, Sandia National Laboratories, Livermore, CA 94550, USA.
Tyler P EcklesBiotechnology and Bioengineering, Sandia National Laboratories, Livermore, CA 94550, USA.
Anchal SinhaBiotechnology and Bioengineering, Sandia National Laboratories, Livermore, CA 94550, USA.
Joseph S SchoenigerSystems Biology, Sandia National Laboratories, Livermore, CA 94550, USA.
Brooke HarmonSystems Biology, Sandia National Laboratories, Livermore, CA 94550, USA.
Robert J MeagherBiotechnology and Bioengineering, Sandia National Laboratories, Livermore, CA 94550, USA.
Vinay AbhyankarDepartment of Biomedical Engineering, Rochester Institute of Technology, Rochester, NY 14627, USA.
Chung-Yan KohBiotechnology and Bioengineering, Sandia National Laboratories, Livermore, CA 94550, USA.

Funding

Microfluidic Platform for Multiplexed DiagnosticsR01AI098853 · NIAID · SANDIA CORP-SANDIA NATIONAL LABORATORIES · PI SINGH, ANUP K. · 2012 to 2015
$3.5M
NIAID NIH HHS R01 AI098853
6 · The paper itself

Abstract

The discovery of the RNA-guided DNA nuclease CRISPR-Cas9 has enabled the targeted editing of genomes from diverse organisms, but the permanent and inheritable nature of genome modification also poses immense risks. The potential for accidental exposure, malicious use, or undesirable persistence of Cas9 therapeutics and off-target genome effects highlight the need for detection assays. Here we report a centrifugal microfluidic platform for the measurement of both Cas9 protein levels and nuclease activity. Because Cas9 from many bacterial species have been adapted for biotechnology applications, we developed the capability to detect Cas9 from the widely-used

Identifiers

PMID31565079
PMCPMC6764754

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.